Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,371.44 374.63 2.68%
TOPIX 1,161.95 25.86 2.28%
HANG SENG 22,813.92 142.66 0.63%

Amsterdam Molecular Therapeutics(in Liquidation) Announces Delisting and Expected Finalisation of Liquidation Process



   Amsterdam Molecular Therapeutics(in Liquidation) Announces Delisting and
                 Expected Finalisation of Liquidation Process

  PR Newswire

  AMSTERDAM, November 6, 2012

AMSTERDAM, November 6, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in
liquidatie) (Euronext: AMT) announces that NYSE Euronext has determined and
announced that as of 19 November 2012, AMT's shares will be delisted from NYSE
Euronext in Amsterdam, the Netherlands with 16 November 2012 being the last
trading date.

On 12 September 2012, the account and justification (rekening en
verantwoording) as prepared by AMT's liquidators was made available for
inspection at the Chamber of Commerce of Amsterdam (De Ruyterkade 5,
Amsterdam) and at AMT's offices (Meibergdreef 61, Amsterdam Zuidoost), and on
14 September 2012 notice of the same was given in a national newspaper. Absent
any surplus following the final settlement of the remaining assets and
liabilities, no plan of distribution (plan van verdeling) was prepared.

Assuming that no action (verzet) will be instituted against the account and
justification, AMT's liquidators expect to finalise the liquidation on or
shortly following 19 November 2012. There will not be any (final)
distributions to AMT shareholders in the context of the finalisation of the
liquidation or otherwise. When the liquidation ends, AMT and its shares shall
cease to exist.

Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues,"
"estimates," "intends," "projects," "goals," "targets" and other words of
similar meaning are intended to identify such forward-looking statements. Such
statements are based on current expectations only. Undue reliance should not
be placed on these statements because, by their nature, they are subject to
known and unknown risks and can be affected by factors that are beyond the
control of AMT (in liquidation). Actual results could differ materially from
current expectations due to a number of factors and uncertainties. AMT (in
liquidation) expressly disclaims any intent or obligation to update any
forward-looking statements herein except as required by law.

Further information on AMT (in liquidation), can be found on AMT (in
liquidation)'s website http://www.amtbiopharma.com .

 

PRN NLD

Contact: For further enquiries: Jörn Aldag, Liquidator, AMT (in liquidation),
Tel : +31-20-566-8014, j.aldag@amtbiopharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement